Chemical Compound

ERAVACYCLINE

CAS Registry Number 1207283-85-9

Back to search Request a Quote

Primary Record

ERAVACYCLINE

In stock: 3,538 g
Purity: 99.0 %
CAS: 1207283-85-9

Compound Identifiers & Properties

CAS: 1207283-85-9
PubChem CID: 54726192
SMILES: CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=C(C(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)NC(=O)CN5CCCC5)F
Canonical SMILES: CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)c(NC(=O)CN5CCCC5)cc(F)c4C[C@H]3C[C@@H]12

Names & Synonyms

ERAVACYCLINE
Xerava
TP-434
eravaciclina
Eravacycline [USAN]
TP434;Eravacycline
1207283-85-9
Eravacycline [USAN:INN]
RefChem:933224
ERAVACYCLINE [MI]
Eravacycline (USAN/INN)
ERAVACYCLINE [INN]
D0LZ7E
Eravacycline dihydrochloride
ERAVACYCLINE [WHO-DD]
orb1709743
TP434
UNII-07896928ZC
CHEMBL1951095
CHEMBL4597183
SCHEMBL10040430
SCHEMBL29359397
GTPL10805
EX-A751
CHEBI:177804
DTXSID401026285
EBC-27317
TP-038
TP-120
TP-170
TP-221
TP-271
TP-787
Tigecycline Impurity 17; Eravacycline
ZINC200151468
CS-7564
DB12329
compound 17j [PMID: 2148514]
07896928ZC
DA-63250
FD136890
HY-16980
NS00072918
J3.052.260E
D10369
EN300-37158604
(4S,4aS,5aR,12aR)-4-(dimethylamino)-7-fluoro-1,10,11,12a-tetrahydroxy-3,12-dioxo-9-[(2-pyrrolidin-1-ylacetyl)amino]-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide
Q15410941
TP-434 (oral, multidrug-resistant bacterial infections)
(4S,4aS,5aR,12aS)-4-(dimethylamino)-7-fluoro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-[2-(pyrrolidin-1-yl)acetamido]-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline
6-Demethyl-7-fluoro-9-(pyrrolizinoacetylamino)-6-deoxytetracycline
Tetracycline analogs (iv, antibiotic), Tetraphase Pharmaceuticals
1-Pyrrolidineacetamide, N-((5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-4-fluoro-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl)-
Tetracycline analogs (bacterial infection), Tetraphase Pharmaceuticals
Tetracycline derivatives (bacterial infection), Tetraphase Pharmaceuticals
Fluorocycline antibiotic (oral, bacterial infection), Tetraphase Pharmaceuticals
TP-434 (oral, multidrug-resistant bacterial infections), Tetraphase Pharmaceuticals
(4S,4aS,5aR,12aR)-4-(dimethylamino)-7-fluoro-1,10,11,12a-tetrahydroxy-3,12-dioxo-9-(2-(pyrrolidin-1-yl)acetamido)-3,4,4a,5,5a,6,12,12a-octahydrotetracene-2-carboxamide
(4S,4aS,5aR,12aR)-4-(dimethylamino)-7-fluoro-1,10,11,12a-tetrahydroxy-3,12-dioxo-9-[2-(pyrrolidin-1-yl)acetamido]-3,4,4a,5,5a,6,12,12a-octahydrotetracene-2-carboxamide
(4S,4aS,5aR,12aR)-4-(dimethylamino)-7-luoro-1,10,11,12a-tetrahydroxy-3,12-dioxo-9-[(2-pyrrolidin-1-ylacetyl)amino]-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide
(4S,4aS,5aR,12aS)-4-(Dimethylamino)-7-fluoro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-((pyrrolidin-1-ylacetyl)amino)-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
(4S,4aS,5aR,12aS)-4-(dimethylamino)-7-fluoro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-(2-(pyrrolidin-1-yl)acetamido)-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
(4S,4aS,5aR,12aS)-4-(dimethylamino)-7-fluoro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-[(2-pyrrolidin-1-ylacetyl)amino]-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide
(4S,4aS,5aR,12aS)-4-(Dimethylamino)-7-fluoro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-[(2-pyrrolidine-1-ylacetyl)amino]-1,4,4a,5,5a,6,11,12a-octahydronaphthacene-2-carboxamide
(4S,4AS,5AR,12AS)-4-(DIMETHYLAMINO)-7-FLUORO-3,10,12,12ATETRAHYDROXY-1,11-DIOXO-9-(2-(PYRROLIDIN-1-YL)ACETAMIDO)-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE
4S,4AS,5AR,12AS)-4-(DIMETHYLAMINO)-7-FLUORO-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-9-((PYRROLIDIN-1-YLACETYL)AMINO)-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE
Dimethylamino-7-fluoro-3,10,12,12a-tetrahydroxy-1 ,11-dioxo-9-(2-pyrrolidin-1-yl-cetylamino)-1,4,4a,5,5a,6,11 ,12a-octahydro-naphthacene-2-carboxylic acid amide
N-[(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-4-fluoro-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-1-pyrrolidineacetamide
YQM